Fexofenadine
- Generic Name
- Fexofenadine
- Brand Names
- Allegra, Allegra-D, Mucinex Non-drowsy Allergy, Wal-fex, Telfast
- Drug Type
- Small Molecule
- Chemical Formula
- C32H39NO4
- CAS Number
- 83799-24-0
- Unique Ingredient Identifier
- E6582LOH6V
- Background
Fexofenadine is an over-the-counter second-generation antihistamine used in the treatment of various allergic symptoms. It is selective for the H receptor, carries little-to-no activity at off-targets, and does not cross the blood-brain barrier - this is in contrast to previous first-generation antihistamines, such as diphenhydramine, which readily bind to o...
- Indication
In the United States, fexofenadine is indicated for the symptomatic treatment of allergic rhinitis in patients ≥2 years old and chronic idiopathic urticaria in patients ≥6 months old. In Canada, fexofenadine carries the same indications but is approved only for patients ≥12 years old. Fexofenadine is also available in combination with pseudoephedrine for the...
- Associated Conditions
- Allergic Rhinitis (AR), Chronic Idiopathic Urticaria, Seasonal Allergic Rhinitis
- Associated Therapies
- Antihistamine
Fexofenadine Versus Gabapentin for Uremic Pruritus in Patients on Regular Hemodialysis
- Conditions
- Interventions
- First Posted Date
- 2024-06-20
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Tanta University
- Target Recruit Count
- 60
- Registration Number
- NCT06466421
- Locations
- 🇪🇬
Tanta University, Tanta, Elgharbia, Egypt
Assessment of the Safety, Tolerability and Pharmacokinetics of AV078 in Healthy Volunteers
- Conditions
- Interventions
- First Posted Date
- 2024-01-16
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- Aeovian Pharmaceuticals, Inc.
- Target Recruit Count
- 136
- Registration Number
- NCT06205381
- Locations
- 🇦🇺
Q-Pharm, Herston, Queensland, Australia
🇦🇺Nucleus Network Pty Ltd, Melbourne, Victoria, Australia
A Study to Assess the Effect of BMS-986419 on the Single Dose Drug Levels of Probe Substrates in Healthy Participants
- Conditions
- Interventions
- First Posted Date
- 2023-07-06
- Last Posted Date
- 2023-10-30
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 22
- Registration Number
- NCT05932277
- Locations
- 🇺🇸
ICON Lenexa, Lenexa, Kansas, United States
A Placebo-controlled Study of 2-day Pre-treatment With Fexofenadine in Seasonal Allergic Rhinitis
- First Posted Date
- 2023-01-20
- Last Posted Date
- 2024-05-16
- Lead Sponsor
- Opella Healthcare Group SAS, a Sanofi Company
- Target Recruit Count
- 95
- Registration Number
- NCT05692154
- Locations
- 🇨🇦
Investigational Site Number : 1240001, Kingston, Ontario, Canada
Fexofenadine in Patients With Active Rheumatoid Arthritis
- First Posted Date
- 2022-03-03
- Last Posted Date
- 2023-11-14
- Lead Sponsor
- October 6 University
- Target Recruit Count
- 80
- Registration Number
- NCT05264025
- Locations
- 🇪🇬
Beni-Suef Hospital, Banī Suwayf, Egypt
🇪🇬Faculty of Medicine - Beni Suef Hospital, Banī Suwayf, Egypt
Non-inferiority Study of Ocrelizumab and Rituximab in Active Multiple Sclerosis
- Conditions
- Interventions
- First Posted Date
- 2020-12-30
- Last Posted Date
- 2024-05-16
- Lead Sponsor
- Rigshospitalet, Denmark
- Target Recruit Count
- 600
- Registration Number
- NCT04688788
- Locations
- 🇩🇰
Department of Neurology, Herlev Hospital, Herlev, Denmark
🇩🇰Department of Neurology, Aalborg University Hospital, Aalborg, Denmark
🇩🇰Department of Neurology, Aarhus University Hospital, Aarhus, Denmark
Histamine H1/H2 Receptors and Training Adaptations
- Conditions
- Interventions
- First Posted Date
- 2020-06-29
- Last Posted Date
- 2024-06-07
- Lead Sponsor
- University Ghent
- Target Recruit Count
- 19
- Registration Number
- NCT04450134
- Locations
- 🇧🇪
Department of Movement and Sports Sciences, Ghent University, Gent, Oost-Vlaanderen, Belgium
Study of KRYSTEXXA® (Pegloticase) Plus Methotrexate in Participants With Uncontrolled Gout
- First Posted Date
- 2019-06-21
- Last Posted Date
- 2024-06-26
- Lead Sponsor
- Amgen
- Target Recruit Count
- 152
- Registration Number
- NCT03994731
- Locations
- 🇺🇸
Arizona Arthritis and Rheumatology Research, PLLC-East, Mesa, Arizona, United States
🇺🇸Axis Clinical Trials, Los Angeles, California, United States
🇺🇸Prohealth Research Center, Doral, Florida, United States
Relation Between Blood Concentration of Colchicine and Response to Colchicine Treatment in Gout Flare
- Conditions
- Interventions
- First Posted Date
- 2019-05-01
- Last Posted Date
- 2024-06-03
- Lead Sponsor
- Assistance Publique - Hôpitaux de Paris
- Target Recruit Count
- 26
- Registration Number
- NCT03933007
- Locations
- 🇫🇷
Hôpital Lariboisière-Service de Rhumatolologie, Paris, France
Fexofenadine Use in Gastroesophageal Reflux Symptoms
- Conditions
- Interventions
- First Posted Date
- 2018-02-07
- Last Posted Date
- 2021-02-17
- Lead Sponsor
- Stanford University
- Target Recruit Count
- 11
- Registration Number
- NCT03425097
- Locations
- 🇺🇸
Stanford Health Care, Redwood City, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.